Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
Open Access
- 1 January 2020
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 91 (1), 58-66
- https://doi.org/10.1136/jnnp-2019-321124
Abstract
Background In PARADIGMS, a double-blind phase III trial in 215 paediatric patients with multiple sclerosis (MS) (10 to <18 years), fingolimod administered for up to 2 years significantly reduced the annualised relapse rate (ARR) and rate of new/newly enlarged T2 (n/neT2) lesions compared with interferon (IFN) beta-1a. Objectives To investigate (1) differences between treatment groups across subpopulations (treatment-naive, younger/prepubertal patients); (2) disability progression. Methods ARRs at 10, 11 and 12 years were estimated based on predefined modelling extrapolations. Changes in Expanded Disability Status Scale (EDSS), and in 3 month (3M) and 6 month (6M) confirmed disability progression (CDP) were evaluated post hoc. Results In the treatment-naive subpopulation, fingolimod reduced ARR and n/neT2 lesions by 85.8% and 53.4%, respectively versus INF beta-1a (both p<0.001), compared with 81.9% and 52.6% in the overall population. Model-based ARR reductions in younger patients (<= 12 years) were 91.9%-94.6%. Twice as many IFN beta-1a-treated than fingolimod-treated patients had worse EDSS scores at study end (20.6% vs 10.5%, p=0.043). Risk reductions in 3M-CDP and 6M-CDP were 77.2% (p=0.007) and 80.2% (p=0.040), respectively. Conclusions Fingolimod in paediatric MS was associated with consistent control of disease activity versus IFN beta-1a (including treatment-naive and younger patients) and resulted in less disability progression for up to 2 years.Keywords
Funding Information
- Novartis Pharma AG
This publication has 27 references indexed in Scilit:
- International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitionsMultiple Sclerosis Journal, 2013
- Role of puberty in multiple sclerosis risk and courseClinical Immunology, 2013
- Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndromeNeurology, 2013
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Difference in Disease Burden and Activity in Pediatric Patients on Brain Magnetic Resonance Imaging at Time of Multiple Sclerosis Onset vs AdultsArchives of Neurology, 2009
- Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple SclerosisArchives of Neurology, 2009
- The biology of CNS remyelinationZeitschrift für Neurologie, 2008
- Natural History of Multiple Sclerosis with Childhood OnsetNew England Journal of Medicine, 2007
- Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelinationNeurobiology of Aging, 2006